Rapid high-performance liquid chromatographic Determination of suramin in plasma of patients With acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC)

O, Teirlynck; Mg, Bogaert; Demedts, Paul; Taelman, H

doi:10.1016/0731-7085(89)80073-1

Cited by 12 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The concentration of suramin in the culture medium was measured by rapid high-performance liquid chromatography (Gold System, Beckman, Berkeley, CA) according to Teirlynck et al (1988).…”

Section: Determination Of Suramin Concentrationmentioning

confidence: 99%

Suramin inhibits proliferation of rat glioma cells and alters N‐cam cell surface expression

Fantini

Guo

Marvaldi

et al. 1990

Intl Journal of Cancer

View full text Add to dashboard Cite

Suramin, a drug used in the treatment of trypanosomiasis and onchocerciasis inhibits growth-factor-induced mitogenesis. We have investigated the effect of suramin on the growth rate and the morphology of C6 glioma cells cultured in the presence of serum or in a serum-free defined medium. Exponentially growing cells were seeded in multi-dish plates (5 x 10(4) cells/2 cm2 well) in DMEM supplemented with 5% fetal calf serum and were continuously exposed to 1 microgram/ml to 1,000 micrograms/ml suramin. Growth rate (determined 9 days after seeding) was reduced by 5%, 33%, 56% and 97%, respectively for suramin concentrations of 1, 10, 100 and 1000 micrograms/ml. Similar results were obtained in serum-free defined medium (DMEM/F12, 1:1, v:v, EGF 5 ng/ml, transferrin 5 micrograms/ml, selenium 10 ng/ml). Moreover, the concentration of suramin in the culture medium remained constant, demonstrating that the drug was not actively metabolized by the cells. Suramin also induced marked changes in cell morphology: the usual bipolar shape of C6 cells evolved toward a more differentiated appearance, with numerous cellular processes allowing a wide number of cell-cell contacts. In parallel, we monitored expression of an adhesion molecule (N-CAM) at both the mRNA and protein levels. Indirect immunofluoresence technique showed an important increase in cell surface N-CAM expression, starting from a dose of 10 micrograms/ml suramin, whereas total cellular content of N-CAM protein as well as its mRNA levels were unaffected. We also observed that the levels of expression of actin and N-CAM mRNAs decreased by a factor of two in cells maintained in defined medium. However, the relative ratio of N-CAM mRNA over actin mRNA was virtually unchanged following suramin treatment. Taken together, our results suggest that suramin (i) exerts a blocking effect of autocrine growth factors, (ii) interferes with the turn-over mechanisms of N-CAM expressed at the cell surface, either by impairing its endocytosis and/or the process of release of the N-CAM 120 isoform.

show abstract

“…The concentration of suramin in the culture medium was measured by rapid high-performance liquid chromatography (Gold System, Beckman, Berkeley, CA) according to Teirlynck et al (1988).…”

Section: Determination Of Suramin Concentrationmentioning

confidence: 99%

Suramin inhibits proliferation of rat glioma cells and alters N‐cam cell surface expression

Fantini

Guo

Marvaldi

et al. 1990

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Suramin levels were assayed using reverse-phase ion chromatography conditions [44, 45, 46]. The LC system consisted of Hitachi’s D-7000 series interfaced with the Windows NT chromatography manager and using the Hitachi L4500 DAD (diode array detector) at 240 n M .…”

Section: Methodsmentioning

confidence: 99%

A Pilot Trial of Suramin in Metastatic Breast Cancer to Assess Antiangiogenic Activity in Individual Patients

et al. 2000

View full text Add to dashboard Cite

Suramin is a polysulfonated naphthylurea with multiple potential mechanisms of action against tumors, including the ability to bind growth factors known to promote tumor angiogenesis. Using an established fixed dosing scheme for the administration of suramin in patients, a pilot study was conducted in patients with progressive, metastatic breast cancer. The primary objective of this trial is to define the effect of suramin on the angiogenic activity in individual patients using in vitro laboratory assays. The secondary objective was to assess the antitumor effect of suramin in a population of metastatic breast cancer patients. No objective tumor responses were observed in any of the 9 patients who received treatment with suramin, however 1 patient did maintain stable disease status. The strength of angiogenic activity present in patient samples was assessed by testing patient plasma in the capillary endothelial cell migration assay. Angiogenic activity followed over time was lowest in patients with the highest suramin concentrations and highest in patients with the lowest suramin concentrations. We conclude that it is feasible to continually monitor the activity of antiangiogenic agents in individual patients without relying on clinical tumor response.

show abstract

Stability of Suramin in Aqueous Solution; Possible Implications for the Search for Suramin Metabolites in Patients

Kassack

Nickel

1996

Archiv der Pharmazie

View full text Add to dashboard Cite

The stability of an aqueous solution of suramin has been determined. The only degradation product detectable by HPLC was the amine precursor 2. The decomposition kinetics of suramin at different temperatures are shown. Because of first order kinetics the Arrhenius equation could not be used to evaluate the decomposition data. A good correlation was obtained between the reaction constants and the temperature (r = 0.9898). After 42 days at 37 degrees C, 2 % of suramin are hydrolysed. Possible implications of our results for the search for suramin metabolites in patients are discussed.

show abstract

Rapid high-performance liquid chromatographic Determination of suramin in plasma of patients With acquired immune deficiency syndrome (AIDS) or AIDS-related complex (ARC)

Cited by 12 publications

References 10 publications

Suramin inhibits proliferation of rat glioma cells and alters N‐cam cell surface expression

Suramin inhibits proliferation of rat glioma cells and alters N‐cam cell surface expression

A Pilot Trial of Suramin in Metastatic Breast Cancer to Assess Antiangiogenic Activity in Individual Patients

Stability of Suramin in Aqueous Solution; Possible Implications for the Search for Suramin Metabolites in Patients

Contact Info

Product

Resources

About